标题
Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis
作者
关键词
-
出版物
LANCET
Volume 397, Issue 10275, Pages 754-766
出版商
Elsevier BV
发表日期
2021-01-28
DOI
10.1016/s0140-6736(21)00184-7
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Neutrophil extracellular trap-associated RNA and LL37 enable self-amplifying inflammation in psoriasis
- (2020) Franziska Herster et al. Nature Communications
- Comparison of Biologics and Oral Treatments for Plaque Psoriasis
- (2020) April W. Armstrong et al. JAMA Dermatology
- TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-blind, Placebo-controlled Trial
- (2020) Seth B. Forman et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Hidradenitis suppurativa
- (2020) Robert Sabat et al. Nature Reviews Disease Primers
- Persistence and Effectiveness of Non-Biologic Systemic Therapies for Moderate-Severe Psoriasis in Adults: a Systematic Review
- (2019) K.J. Mason et al. BRITISH JOURNAL OF DERMATOLOGY
- Prevalence and characteristics of psoriasis in Denmark: findings from the Danish skin cohort
- (2019) Alexander Egeberg et al. BMJ Open
- Inhibition of the Interleukin-36 Pathway for the Treatment of Generalized Pustular Psoriasis
- (2019) Hervé Bachelez et al. NEW ENGLAND JOURNAL OF MEDICINE
- Imiquimod-Induced Psoriasis in Mice Depends on the IL-17 Signaling of Keratinocytes
- (2019) Sonja Moos et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- IL-17E (IL-25) enhances innate immune responses during skin inflammation
- (2019) Luisa Senra et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Brodalumab for the treatment of plaque psoriasis: up-to-date
- (2019) Kristen M. Beck et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study
- (2019) Youssef A Elnabawi et al. CARDIOVASCULAR RESEARCH
- Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study
- (2019) Irina Gasslitter et al. ARCHIVES OF DERMATOLOGICAL RESEARCH
- Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials
- (2019) Stefan Schreiber et al. ANNALS OF THE RHEUMATIC DISEASES
- Systematic review and meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease
- (2019) Christopher Ma et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Efficacy and safety of mirikizumab ( LY 3074828) in the treatment of moderate‐to‐severe plaque psoriasis: results from a randomized phase II study
- (2019) K. Reich et al. BRITISH JOURNAL OF DERMATOLOGY
- Metabolic and Innate Immune Cues Merge into a Specific Inflammatory Response via the UPR
- (2019) Denis A. Mogilenko et al. CELL
- Effectiveness and safety of secukinumab in Italian patients with psoriasis: an 84 week, multicenter, retrospective real-world study
- (2019) Matteo Megna et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- A safety review of recent advancements in the treatment of psoriasis: analysis of clinical trial safety data
- (2019) Sree S. Kolli et al. Expert Opinion On Drug Safety
- The IL-23/IL-17 pathway in human chronic inflammatory diseases—new insight from genetics and targeted therapies
- (2019) Elisabetta Bianchi et al. GENES AND IMMUNITY
- The IL-17 Family of Cytokines in Health and Disease
- (2019) Mandy J. McGeachy et al. IMMUNITY
- The Immunobiology of the Interleukin-12 Family: Room for Discovery
- (2019) Elia D. Tait Wojno et al. IMMUNITY
- T cell pathology in skin inflammation
- (2019) Robert Sabat et al. Seminars in Immunopathology
- Psoriasis treat to target: defining outcomes in psoriasis using data from a real world, population‐based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR )
- (2019) S.K. Mahil et al. BRITISH JOURNAL OF DERMATOLOGY
- Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165
- (2019) Stephen T. Wrobleski et al. JOURNAL OF MEDICINAL CHEMISTRY
- Incidence and prevalence of psoriasis in Israel between 2011 and 2017
- (2019) Y. Schonmann et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial
- (2019) Kristian Reich et al. LANCET
- Autoreactive T-Lymphocytes in Inflammatory Skin Diseases
- (2019) Wolf-Henning Boehncke et al. Frontiers in Immunology
- Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial
- (2019) Kristian Reich et al. LANCET
- Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response
- (2019) Laura M. Sawyer et al. PLoS One
- Emerging Topical and Systemic JAK Inhibitors in Dermatology
- (2019) Farzan Solimani et al. Frontiers in Immunology
- Efficacy and Safety of Ixekizumab in a Randomized, Double-Blinded, Placebo-Controlled Phase 3b Study of Patients with Moderate-to-Severe Genital Psoriasis
- (2018) C. Ryan et al. BRITISH JOURNAL OF DERMATOLOGY
- Guselkumab for the treatment of psoriasis
- (2018) Matteo Megna et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials
- (2018) Lian Cui et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Resident T Cells in Resolved Psoriasis Steer Tissue Responses that Stratify Clinical Outcome
- (2018) Irène Gallais Sérézal et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials
- (2018) Mark G. Lebwohl et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial
- (2018) Kim A. Papp et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study
- (2018) Atul Deodhar et al. LANCET
- HLA-C*06:02-independent, gender-related association of PSORS1C3 and PSORS1C1/CDSN single-nucleotide polymorphisms with risk and severity of psoriasis
- (2018) Andrzej Wiśniewski et al. MOLECULAR GENETICS AND GENOMICS
- The psoriasis-protective TYK2 I684S variant impairs IL-12 stimulated pSTAT4 response in skin-homing CD4+ and CD8+ memory T-cells
- (2018) C. Enerbäck et al. Scientific Reports
- Transcription Factor Retinoid-Related Orphan Receptor γt: A Promising Target for the Treatment of Psoriasis
- (2018) Lipeng Tang et al. Frontiers in Immunology
- IL-36γ Is a Strong Inducer of IL-23 in Psoriatic Cells and Activates Angiogenesis
- (2018) Charlie Bridgewood et al. Frontiers in Immunology
- Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study
- (2018) Dominique Baeten et al. ANNALS OF THE RHEUMATIC DISEASES
- Candidate long-range regulatory sites acting on the IL17 pathway genes TRAF3IP2 and IL17RA are associated with psoriasis
- (2018) Joanne Nititham et al. EXPERIMENTAL DERMATOLOGY
- Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
- (2018) Kenneth B Gordon et al. LANCET
- Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis
- (2018) Kim Papp et al. NEW ENGLAND JOURNAL OF MEDICINE
- OUP accepted manuscript
- (2018) RHEUMATOLOGY
- The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond
- (2018) Nicolo Costantino Brembilla et al. Frontiers in Immunology
- Efficacy and safety of switching to ixekizumab in secukinumab nonresponder psoriatic patients: results from a multicenter experience
- (2018) A. Conti et al. BRITISH JOURNAL OF DERMATOLOGY
- Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks
- (2018) Esther von Stebut et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Biological Effects of IL-26 on T Cell–Mediated Skin Inflammation, Including Psoriasis
- (2018) Takumi Itoh et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- The IL-1 pathway is hyperactive in Hidradenitis suppurativa and contributes to skin infiltration and destruction
- (2018) Ellen Witte-Händel et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicentre retrospective study
- (2018) G. Deza et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial
- (2018) Désirée van der Heijde et al. LANCET
- Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial
- (2018) Philip Mease et al. LANCET
- Genetic signature to provide robust risk assessment of psoriatic arthritis development in psoriasis patients
- (2018) Matthew T. Patrick et al. Nature Communications
- Association of Psoriasis With Inflammatory Bowel Disease
- (2018) Yun Fu et al. JAMA Dermatology
- IL-17F regulates psoriasis-associated genes through IκBζ
- (2017) Trine Bertelsen et al. EXPERIMENTAL DERMATOLOGY
- Exome-wide association study reveals novel psoriasis susceptibility locus at TNFSF15 and rare protective alleles in genes contributing to type I IFN signalling
- (2017) Nick Dand et al. HUMAN MOLECULAR GENETICS
- Clinically resolved psoriatic lesions contain psoriasis-specific IL-17–producing αβ T cell clones
- (2017) Tiago R. Matos et al. JOURNAL OF CLINICAL INVESTIGATION
- Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial
- (2017) Andrew Blauvelt et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial
- (2017) Kristian Reich et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- European consensus statement on phenotypes of pustular psoriasis
- (2017) A.A. Navarini et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Richard B Warren et al. LANCET
- Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial
- (2017) Peter Nash et al. LANCET
- Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
- (2017) Kristian Reich et al. LANCET
- Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study
- (2017) Brian G Feagan et al. LANCET
- JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
- (2017) Daniella M. Schwartz et al. NATURE REVIEWS DRUG DISCOVERY
- An analysis of IL-36 signature genes and individuals with IL1RL2 knockout mutations validates IL-36 as a psoriasis therapeutic target
- (2017) Satveer K. Mahil et al. Science Translational Medicine
- Large scale meta-analysis characterizes genetic architecture for common psoriasis associated variants
- (2017) Lam C. Tsoi et al. Nature Communications
- Ultraviolet B Inhibits IL-17A/TNF-α-Stimulated Activation of Human Dermal Fibroblasts by Decreasing the Expression of IL-17RA and IL-17RC on Fibroblasts
- (2017) Li Yin et al. Frontiers in Immunology
- Anti-interleukin and interleukin therapies for psoriasis: current evidence and clinical usefulness
- (2017) Ya-Chu Tsai et al. Therapeutic Advances in Musculoskeletal Disease
- Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study
- (2016) V.J. Ludbrook et al. BRITISH JOURNAL OF DERMATOLOGY
- A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis
- (2016) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis
- (2016) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis
- (2016) Robert Bissonnette et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Characterization of TNF-α– and IL-17A–Mediated Synergistic Induction of DEFB4 Gene Expression in Human Keratinocytes through IκBζ
- (2016) Claus Johansen et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Keratinocyte-Derived IL-17E Contributes to Inflammation in Psoriasis
- (2016) Luisa Senra et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Defining the functional binding sites of interleukin 12 receptor β1 and interleukin 23 receptor to Janus kinases
- (2016) Doreen M. Floss et al. MOLECULAR BIOLOGY OF THE CELL
- Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
- (2016) Kenneth B. Gordon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity
- (2016) C. A. Dendrou et al. Science Translational Medicine
- IL-12 protects from psoriasiform skin inflammation
- (2016) Paulina Kulig et al. Nature Communications
- Psoriasis
- (2016) Jacqueline E. Greb et al. Nature Reviews Disease Primers
- Melanocyte antigen triggers autoimmunity in human psoriasis
- (2015) Akiko Arakawa et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Psoriasis
- (2015) Wolf-Henning Boehncke et al. LANCET
- Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
- (2015) Christopher E M Griffiths et al. LANCET
- Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial
- (2015) Hervé Bachelez et al. LANCET
- Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2015) Iain B McInnes et al. LANCET
- Selective targeting of the IL23 pathway: Generation and characterization of a novel high-affinity humanized anti-IL23A antibody
- (2015) Sanjaya Singh et al. mAbs
- Beyond passive immunization: toward a nanoparticle-based IL-17 vaccine as first in class of future immune treatments
- (2015) John Foerster et al. Nanomedicine
- Clinical improvement in psoriasis with specific targeting of interleukin-23
- (2015) Tamara Kopp et al. NATURE
- Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
- (2015) Dominique Baeten et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
- (2015) Mark Lebwohl et al. NEW ENGLAND JOURNAL OF MEDICINE
- IL-4 abrogates TH17 cell-mediated inflammation by selective silencing of IL-23 in antigen-presenting cells
- (2015) Emmanuella Guenova et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Immunology of Psoriasis
- (2014) Michelle A. Lowes et al. Annual Review of Immunology
- IL-23 Promotes Maintenance but Not Commitment to the Th17 Lineage
- (2014) G. L. Stritesky et al. JOURNAL OF IMMUNOLOGY
- Epidermal Th22 and Tc17 Cells Form a Localized Disease Memory in Clinically Healed Psoriasis
- (2014) S. Cheuk et al. JOURNAL OF IMMUNOLOGY
- IL-19 Is a Component of the Pathogenetic IL-23/IL-17 Cascade in Psoriasis
- (2014) Ellen Witte et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials
- (2014) Richard G. Langley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor Necrosis Factor Receptor Signaling in Keratinocytes Triggers Interleukin-24-Dependent Psoriasis-like Skin Inflammation in Mice
- (2013) Snehlata Kumari et al. IMMUNITY
- Keratinocyte Overexpression of IL-17C Promotes Psoriasiform Skin Inflammation
- (2013) A. Johnston et al. JOURNAL OF IMMUNOLOGY
- Characterization of Innate Lymphoid Cells in Human Skin and Blood Demonstrates Increase of NKp44+ ILC3 in Psoriasis
- (2013) Federica Villanova et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Therapeutic opportunities of the IL-22–IL-22R1 system
- (2013) Robert Sabat et al. NATURE REVIEWS DRUG DISCOVERY
- An In-Depth Characterization of the Major Psoriasis Susceptibility Locus Identifies Candidate Susceptibility Alleles within an HLA-C Enhancer Element
- (2013) Alex Clop et al. PLoS One
- IL-29 Is Produced by TH17 Cells and Mediates the Cutaneous Antiviral Competence in Psoriasis
- (2013) K. Wolk et al. Science Translational Medicine
- Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity
- (2012) Lam C Tsoi et al. NATURE GENETICS
- Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells
- (2011) Kamran Ghoreschi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Inter-Regulation of Th17 Cytokines and the IL-36 Cytokines In Vitro and In Vivo: Implications in Psoriasis Pathogenesis
- (2011) Yijun Carrier et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- TNFAIP3 Gene Polymorphisms Are Associated with Response to TNF Blockade in Psoriasis
- (2011) Trilokraj Tejasvi et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5
- (2011) Xiang-Ping Yang et al. NATURE IMMUNOLOGY
- The IL23R R381Q Gene Variant Protects against Immune-Mediated Diseases by Impairing IL-23-Induced Th17 Effector Response in Humans
- (2011) Paola Di Meglio et al. PLoS One
- Angiogenesis drives psoriasis pathogenesis
- (2010) Regina Heidenreich et al. INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY
- Deficiency of IL-22 Contributes to a Chronic Inflammatory Disease: Pathogenetic Mechanisms in Acne Inversa
- (2010) K. Wolk et al. JOURNAL OF IMMUNOLOGY
- A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti–interferon-alfa monoclonal antibody, in subjects with chronic psoriasis
- (2010) Robert Bissonnette et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Generation of pathogenic TH17 cells in the absence of TGF-β signalling
- (2010) Kamran Ghoreschi et al. NATURE
- A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1
- (2010) Amy Strange et al. NATURE GENETICS
- The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: A novel immunological cascade with potential relevance in psoriasis
- (2009) Kerstin Wolk et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Janus kinases in immune cell signaling
- (2009) Kamran Ghoreschi et al. IMMUNOLOGICAL REVIEWS
- Th17 Cytokines Stimulate CCL20 Expression in Keratinocytes In Vitro and In Vivo: Implications for Psoriasis Pathogenesis
- (2009) Erin G. Harper et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-γ are not
- (2009) Kerstin Wolk et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Psoriasis genome-wide association study identifies susceptibility variants within LCE gene cluster at 1q21
- (2009) Xue-Jun Zhang et al. NATURE GENETICS
- Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways
- (2009) Rajan P Nair et al. NATURE GENETICS
- Selectivity and therapeutic inhibition of kinases: to be or not to be?
- (2009) Kamran Ghoreschi et al. NATURE IMMUNOLOGY
- Psoriasis Is Characterized by Accumulation of Immunostimulatory and Th1/Th17 Cell-Polarizing Myeloid Dendritic Cells
- (2008) Lisa C. Zaba et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started